Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known		
		Application Number	10/738,423	
INICODM	ATION DISCLOSURE	Filing Date	December 16, 2003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	KING, et al.	
		Art Unit	1633	
(Use	as many sheets as necessary)	Examiner Name	Qian Janice LI	
Sheet 1	of 11	Attorney Docket Number	873-7-US	

Examiner Initials*	Cite No.	Document Number Number-Kind Code ^{2 (Kisson)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	^{US-} 6,962,696	11-08-2005	Bermudes, et al.	
	2	^{US-} 6,955,953	10-18-2005	Yamazaki, et al.	
	3	^{US-} 6,605,286	08-12-2003	Steidler, et al.	
***************************************	4	^{US-} 6,150,170	11-21-2000	Powell, et al.	
	5	^{US-} 2004-0229338 A1	11-18-2004	King, et al.	
	6	^{US-} 2005-0249706 A1	11-10-2005	Bermudes, et al.	
	7	US- 11/627,743	01-26-2007	King, et al.	
	8	^{US-} 08/486,422	06-07-1995	Pawelek, et al.	
	9	^{US-} 10/723,570	11-24-2006	Pawelek, et al.	
	10	^{US-} 11/117,085	04-28-2005	Bermudes, et al.	
	11	^{US-} 11/064,533	02-23-2005	Bermudes, et al.	
	12	^{US-} 11/082,544	03-17-2005	Bermudes, et al.	
	13	^{US-} 09/724,390	11-28-2000	Bermudes, et al.	
		US-		THE PARTY OF THE P	
		US-			·
		US-			
•		US-			
	endered de de la constante de	US-			
	,	US-			

			GN PATENT DOCU	IMENTS	***************************************	M
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,		
	Country Code ² "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	abblicatif of Otto Operment	Where Relevant Passages Or Relevant Figures Appear	T ⁵	
	14	EP 0833660	12-20-2006	Yale University, et al.		
	15	EP 1012232	06-28-2000	Vion Pharmaceuticals, Inc., et el.		
	16	WO/1995/009655	04-13-1995	The Operations of the United States of Appareous, et al.		
	17	WO/2001/025397	12-04-2001	Vion Pharmaceuticals, Inc. et al.		
	18	WO/1992/015689	09-17-1992	Charles, et al.		
	19	AU 719446	08-24-2000	Yale University, et al.		

,			
Examiner		Date	
Signature	(O. Janice Fi/ (03/10/2009)	Considered	
0.9.10.0.0	ration En (our to Eco)	Sommerce	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next continunication to applicant. Applicant's unique citation designation number (optional), Seek Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiatily is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Complete if Known

 Application Number
 10/738,423

 Filing Date
 December 16, 2003

 First Named Inventor
 KING, et al.

 Art Unit
 1633

 Examiner Name
 Qian Janice U

 Attorney Docket Number
 873-Z-US

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.	Document Number Number-Kind Code ^{2 Meson}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-	AND ASSESSMENT OF THE PROPERTY		
······		US-		······································	
		US-			
***************************************		US-			
		US-			
		US-			
***************************************		Us-	<u> </u>	······	
		US-			
		US-			
	,	US-			
		U\$-			
		US-			
		US-			····
······································	•••••	US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
(4.8800000000000000000000000000000000000		US-		**************************************	***

		FOREIGN	PATENT DOCL	IMENTS		
Examiner Cite Initiats* No.	Foreign Patent Document	Publication Date	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ Number **Kind Code ⁵ (if knows)	MM-DD-YYYY	· ·	Or Relevant Figures Appear	ľ
	20	AU 783714	03-23-2006	VION Pharmaceuticals, Inc., et al.		
•	21	AU 749695	07-04-2002	VION Pharmaceuticals, Inc. et al.		
	22	CN ZL96196140.6	02-18-2004	Yale University, et al.		L
	23	CN ZL98811030.X	04-26-2006	VION Pharmaceuticals, Inc. et al.		
	24	HK 1017253	07-30-2004	Yale University, et al.		L
	25	HK 1033956	11-17-2006	VION Pharmaceuticals,		_

Examiner	(A 1 1 1 1 1 1 1 1.	Date	
Signature	/Q. Janice Li/ (03/10/2009)	Considered	
	,	1	3

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplc.gov or MPEP 901-04. Enter Office that issued the document, by the two-fotter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the suppopriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form anxior suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/58/08A (04-03)

Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Raduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Complete if Known

 Application Number
 10/738,423

 Filing Date
 December 16, 2003

 First Named Inventor
 KING, et al.

 Art Unit
 1633

 Examiner Name
 Qian Janice LI

 Attorney Docket Number
 873-Z-US

	******		U. S. PATENT	DOCUMENTS	
Examiner initials*	Cite No.1	Document Number Number-Kind Code ^{2 (Number)} US-	Publication Date MM-DD-YYYY	Name of Patentae or Applicant of Cited Document	Pages, Columns, Lines, Where Refevent Passages or Relevent Figures Appear
***************************************		Number-Yand Code			
		<u> </u>			
		US-			
		US-			
************		US-			
***************************************		US-	9		
		US-			
		US-	•		
		US-			
		US-			•
		US-			
		US-			
***************************************		US-			***************************************
		US-			- Company of the Comp
***************************************	<u> </u>	US-			
		US-			
		US-			***************************************
		US-			·
		US-		· · · · · · · · · · · · · · · · · · ·	
•••••		U\$-			

	•••••	FORE	IGN PATENT DOCU	MENTS		
Examiner Cite Initiats* No.1		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages	
	Country Code ³ "Number * "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T6	
	26	JP 3482213	10-10-2003	Yale University, et al.		
	27	KR 0435932	06-03-2004	Yale University, et al.		
***************************************	28	NZ 312341	09-08-1999	Yale University, et al.		
	29	NZ 503376	10-25-2002	VION Pharmaceuticals, Inc., et al.		
	30	NZ 518354		VION Pharmacouticals, Inc., et al.		
	31	SG 51176	12-07-1998	Yale University, et al.		

Examiner		Date	1
Signatura	// Janica I // // // // // // // // // // // // /	Considered	
Contract of	/Q. ganice in (00/10/2005)	} 00000000	

"EXAMINER: Initial if reference considered, whether or not detain is in conformance with MPEP 609. Draw line through distinn if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 301.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patient stocuments, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/738,423 Filing Date December 16, 2003 INFORMATION DISCLOSURE First Named Inventor KING, et al. STATEMENT BY APPLICANT Art Unit 1633 (Use as many sheets as necessary) Examiner Name Qian Janice LI Sheet 4 873-Z-US Attorney Docket Number

······································	****		U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ³	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relayant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (Windows)} US-			1,2
		us-			
***************************************		US-			
***************************************		US-	—		
		US-			
		US-			
·····		US-			
		US-			
***************************************		US-			
		US-			
***************************************		US-			
		US-			
****		US-			
**********		US-			
		US-			
***************************************		US-			
•••••		US-			***
		US-	<u> </u>	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
		DS-	-		

		FOREIGN	PATENT DOCL	MENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ² "Number" "Kind Code ⁸ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	L
	32	SG 71486	04-30-2004	VION Pharmacouticals, Inc., et al.		
	33	ZA 98/8289	05-26-1999	VION Pharmaceuticals, Inc., et al.		
	34	EP 1261369	12-04-2002	Vion Pharmacouticals, Inc., et al.		
	35	BR 9609016-2	06-05-1996	Yale University, et al.		
	36	BR 9812079-4	03-10-2000	VION Pharmaceuticals, Inc., et al.		
***************************************	37	BR 0014491-6	04-04-2002	VION Pharmaceuticals,		

Examiner /Q. Janice Li/ (03/10/2009)	Date Considered

"EXAMINER" Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usptc.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionar for Patents, Washington, DC 20231.

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

Substitute for form 1449/PTO

Sheet |5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 111

 Complete if Known

 Application Number
 10/738,423

 Filing Date
 December 16, 2003

 First Named Inventor
 KING, et al.

 Art Unit
 1633

 Examiner Name
 Qian Janice Ll

 Aftomey Docket Number
 873-Z-US

			U. S. PATENT D	OCUMENTS	······································
Examiner Initials*	Cite No.'	Document Number	Publication Date MM-DD-YYYY	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Refevent Passages or Refevent Figures Appear
		Number-Kind Code ^{2 (9 homes)} US-			1,90,001,90,001
		US-			
		US-			
		N8-			
		US-		·····	
		US-			
**********		US-		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
		US-		****	
************		US-			
		US-		······································	
***************************************		US-			
		US-		~~~~	
- 24 - Marie A. Marie		US-		······································	
***********		US-			
		US-			
***************************************		US-		·	
		US-			
	•••	US-	-	······	
***************************************		US	1		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T
HHOSES	140.	Country Code ³ Number ⁴ "Kind Code ² (# known)	MM-DD-YYYY	Abbicant of Cited Document	Or Relevant Figures Appear	TS
	38	CA 2,224,075	12-08-1997	Yale University, et al.		
***************************************	39	CA 2,302,866	03-03-2000	VION Pharmaceuticals, Inc., et al.		
	40	CA 2,386,465	04-02-2002	VION Pharmaceuticals, Inc., et al.		
	41	CN 00816714.1	08-24-2000	VION Pharmaceuticals, Inc., et al.		
	42	HK 03108220,2	11-12-2003	VION Pharmaceuticals, Inc., et al.		
•	43	IL 134936	07-03-2000	VION Pharmaceuticals,		

_				
Examiner	(A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Date	
Signature	/Q. Janice Li/ (03/10/2009)	•	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.uscto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document." Kind of document by the expropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting this completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commence, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20234.

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, so persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 11

Sheet 6

Application Number 10/738,423 Filing Date December 16, 2003 First Named Inventor KING, et al. Art Unit 1633 Examiner Name Qian Janice Li Altorney Docket Number 873-Z-US

	·	·	U. S. PATENT I	OCUMENTS	
Examinar Intliais*	Cite No.1	Document Number Number-Kind Code ^{2 Minoord}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-		······	
		US-			
	·	US-	-	······	
	 	US-			
		US-		······································	***************************************
		US-			
		US-			
		US-			
***************************************		US-	~		
***************************************		US-		·····	
		US-	_		
		US-			
***************************************	**********	US-			
		Næ-		•	
******************		US-			
•••••		US-		······································	
		US-			
		US-			
		US-	1	······································	

		FORE	GN PATENT DOCL	JMENTS	······································	
Examiner Initials*	Cites No.1	Foreign Patent Document	Publication Date	Name of Patentae or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ³ Kind Code ² (# known)	MM-DD-YYYY		Or Relevant Figures Appear	72
	44	IL 148933	03-27-2002	VION Pharmaceuticals, Inc., et al.		
	45	JP 2000-510842	03-10-2000	VION Pharmacauticals, Inc., et al.		
	J	JP 2001-528552	04-04-2002	VION Pharmaceuticals, inc., et al.		
	47	KR 7002535/2000	03-10-2000	VION Pharmaceuticals, Inc., et al.		
	48	KR 7004371/2002	04-04-2002	VION Pharmaceuticals, Inc., et al		
	49	MX 979439	12-03-1997	Yale University, et al.	·	1

Examiner	10 Innian 1 if 100/40/0000	Date
Signature	ra. Janice Lii (USA UIZUUB)	Considered
	•	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. This information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/38/06A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Under the Paperwor	k Reduction Act of 1995, no persons are required t	o respond to a collection of information	tion unless it contains a valid OMB control in	umber.
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			mplete if Known	
		Application Number	10/738,423	
		Filing Date	December 16, 2003	
		First Named Inventor	KING, et al.	
		Art Unit	1633	
		Examiner Name	Qian Janice LI	
Sheet 7	of 11	Attorney Docket Number	873-Z-US	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ^{2 (Khows)}	Publication Date MM-DD-YYYY	Name of Petentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
***************************************	†	US-		in terretaria de la composition della compositi	
***************************************	1	US-		~	
		US-		××××××××××××××××××××××××××××××××××××××	
		US-		······································	······································
		US-			
		US-			
		US-			
		NS-			
		US-			
		US-			
######################################		US-			
	ļ	US-		······································	
***********		US- US-		*************************************	
	ļ	US-	<u> </u>		
***************************************		US-			
		Wo-			

	***************************************		IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Cods ³ "Number *"Kind Code ⁵ (if known)	MM-DD-YYYY	,,,	Or Relevant Figures Appear	1
	50	MX 2000-002355	03-08-2000	VION Pharmaceuticals, Inc., et al.		
	51	MX 2002-003384	04-03-2002	VION Pharmaceuticals, Inc., et al.		
	52	SG 2002-01817-4	04-01-2002	VION Pharmaceuticals, Inc., et al.		
	83	JP 62-145026	06-29-1987	Advance KK		
	84	JP 06-298657	10-25-1994	Nippon Shoji KK		
	85	JP 01-180830	07-18-1989	Kayaku KK		

Examiner	1.00 c 3 c 1.1 c 1.2 c 1	Date	
Signature	/Q. Janice Li/ (03/10/2009)	Considered	
O(G) (OLO) O	, a. vanno en (von ronzovo)	Ontracelen	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usoto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emparor must precede the sental number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/39/2903, OMS 9651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Once the Paperwork Reduction Act of 1995, no persons are required to Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/738,423	
INFORMATION DISCLOSURE	Filing Date	December 16, 2003	
	First Named Inventor	KING, et al.	
STATEMENT BY APPLICANT	Art Unit	1633	
(Use as many sheets as necessary)	Examiner Name	Qian Janice LI	
Street 8 of 11	Attorney Docket Number	873-Z-US	

Examiner	1036	P	U. S. PATENT I	Name of Professional Contract	200
Exammer Initials*	Cite No. ¹	Document Number Number-Kind Code* (***********************************	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-	****		
		US-		•••••	
······································		US-			
***************************************		US-			
		US-			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T [®]			
	86	Country Codes' Number * 'Kind Codes' (if known) JP 63-101328	05-06-1988	Shionogi & Co.					
						-			

Examiner Signature	/Q. Janice Li/ (03/10/2009)	Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.usrte.gov or MPEP 901.04." Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document." Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here it English language Translation is attached.

Traissation is enactived.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (02-03) Approved for use through 04/30/2003, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<u>Un</u>	der the Paperwork Red	uction A	ct of 1995, no persons a	e required to respond to a collection	of information unless it contains a valid OMB control Complete if Known	number.
Substitu	ite for form 1449/PTO			Application Number	10/738,423	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 16, 2003	
STATEMENT BY APPLICANT				First Named Inventor	KING, et al.	
	ittee ee mans aka			Art Unit	1633	
(Use as many sheets as necessary)				Examiner Name	Qian Janice LI	
Sheet	9	of	11	Attorney Docket Number	873-Z-US	

of 11

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	53	Brazilian Examiner's Report for Yale University, Brazilian App'l No. Pl-9609016-2, filed June 5, 1996, Dated July 18, 2006	
	54	Mexican Search Report for Yale University, Mexican App'l No. 979439, Filed December 3, 1997, Dated June 29, 2007	
	55	Israeli Office Action for Yale University, et al., Israeli App'l No. 134936, Filed July 3, 2000, Dated April 11, 2007	
	56	U.S. Office Action for Bermudes, et al., U.S. Serial No. 11/064,533, Filed February 23, 2005, Dated March 12, 2007	
	57	Bell, et al., 1990, "Molecular genetic analysis of an FNR-dependent anaerobically inducible Escherichia coli promoter," Molec. Microbiol. 4:1753-63	
	58	Clarke, S., 2001, "Diarrhoeagenic Escherichia coli – an emerging problem?" Diagnostic Microbiol. and Infect. Disease 41:93-98	
	59	Cunningham, C. and Nemunaitis, J., 2001, "Recombinant DNA advisory committee meeting, June 14-15, 2001: Protocols reviewed," Human Gene Therapy 12:1594-1596	
	60	Deonarain, et al., 1995, "Genetic delivery of enzymes for cancer therapy," Gene Therapy, Vol. 2, No. 4:235-244	
	61	Dinarello, et al., 1991, "Blocking IL-1:Interleukin-1 receptor antagonist in vivo and in vitro," Immunology Today 12(11):404-410	
	62	Fairweather, et al., 1990, "Use of live attenuated bacteria to stimulate immunity," Res. Microbiol. 141:769-773	

Promises	Date
Examiner (O Innion Li) (OQ/40/9000)	Date
Signature /Q. Jarrica LV (03/10/2009)	Considered

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentisitly is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/068 (02-03)

Approved for use through 04/30/2003, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ute for form 1449/PTO			Complete If Known		
				Application Number	10/738,423	
INF	ORMATION	V DIS	SCLOSURE	Filing Date	December 16, 2003	
STA	ATEMENT I	A YE	PPLICANT	First Named Inventor	KING, et al.	•
	(Usa as many sh	. 20 2002	terres anui	Art Unit	1633	
(and an Alary Shared 25 Moreovary).				Examiner Name	Qian Janice LI	
Sheet	10	of	11	Attorney Docket Number	873-Z-US	J

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
	63	Fairweather, et al., 1990, "Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier," Infect Immunity, 58:1323-26	
	64	Galanos, et al., 1969, "A new method for the extraction of R. lipopolysaccharides," European J. Biochem. 9:245-249	
	65	Huber, et al., 1994, "Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase," Proc. Natl. Acad. Sci. USA 91:8302-8306	
	66	Jain, et al., 2001, "Use of bacteria as anticancer agents," Exp. Opin. Biol. Ther. 1(2):291-300	
	67	Jayaraman, et al., 1988, "The nirB promoter of Escherischia coli: Location of nucleotide sequences essential for regulation by oxygen, the FNR protein and nitrite," Molec, Microbiol, 2:527-530	
	68	Littler, et al., 1992, "Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir," Nature 358:160-162	
	69	Low, et al., 1998, "Disruption of the Salmonella msb8 gene suppresses virulence and TNFalpha induction yet retains tumor-targeting in vivo," Proceedings of the American Association for Cancer Research Annual Meeting 39:60, XP001182904	
	70	Morrison, et al., 1994, "Current status of bacterial endotoxins," ASM News 60:479-484	
	71	Nemunaitis, et al., 2003, "Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients," Cancer Gene Ther. 10:737-44	
	72	Pawelek, et al., 1997, "Tumor-targeted Salmonella as a novel anti-Melanoma vector," Melanoma Research, 4th World Conference on Melanoma, Sydney, Australia, June 10-14, 1997, Vol. 7 (Suppl. 1)	

· · · · · · · · · · · · · · · · · · ·	
Examiner IA Inches IV IA IA IA IA IA IA IA	Date
4 T. T. 1 /G. 38000 13/ (U.S/10/2009)	232
Signature	Considered
Olg. Mater 0	CAMBINOTON

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with flext communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is strached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Dependment of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/086 (02-03)
Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/738,423	
INFORMATION DISCLOSURE	Filing Date	December 16, 2003	
STATEMENT BY APPLICANT	First Named Inventor	KING, et al.	
(Use as many sheets as necessary)	Art Unit	1633	
1000 as many strate to novecom y	Examiner Name	Qian Janice Ll	
Sheet 11 of 11	Attorney Docket Number	873-Z-US	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number(s), publisher, city and/or country where published.		T ²
	73	Yu, et al., 2004, "Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins," Nat. Biotechnol. 2004, Mar;22(3):313-20	
	74	Sullivan, et al., 1992, "A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells," Nature 358:162-164	
	75	U.S. Office Action for Bermudes et al., U.S. Serial No. 11/064,533, (Atty. Dkt. #871-BAA-US) Filed February 23, 2005, dated October 3, 2006	
	76	U.S. Office Action for Bermudes et al., U.S. Serial No. 11/064,533, (Atty. Dkt. #871-BAA-US) Filed February 23, 2005, dated May 4, 2007	
	77	Notice of Allowance and Fee(s) Due for Bermudes et al., U.S. Serial No. 11/064,533, (Atty. Dkt. #871-BAA-US) Filed February 23, 2005, dated August 1, 2007	
	78	U.S. Office Action for Bermudes et al., U.S. Serial No. 11/117,085 (Atty. Dkt. #871-AZB-US) Filed April 28, 2005, dated July 5, 2007	
	79	Vion Pharmaceuticals, Inc., et al., European Application No. 98 94 6891, September 9, 1998, "Genetically Modified Tumor-Targeted Bacteria with Reduced Virulence"	
	80	European Communication for VION Pharmaceuticals, Inc., European App'l No. 98946891.3 (Atty. Dkt. #871-AB-PCT-EPO), Filed September 9, 1998, Dated April 10, 2007	
	81	European Communication for VION Pharmaceuticals, Inc., European App'l No. 00 957 764.4 (Atty. Dkt. #873-PCT-EPO), Filed May 3, 2002, Dated October 26, 2006	
	82	International Publication No. WO/1998/053854, March 12, 1998, The Research Foundation of State University of New York, et al., "Antigen Delivery System"	

********	,		
Examiner		Date	
Signature	/Q. Janice Li/ (03/10/2009)	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.